Business Credit Business Travel Franchising Personal Finance Sales & Selling Technology Women in Business Careers E-Commerce & Internet Finance & Accounting Labor & Employment Management Marketing & Advertising Operations Starting a Business > See All

by Title A-H by Title I-P by Title Q-Z > See All

Business Intelligence Small Business Blog Business Planning E-Commerce & Internet Finance & Accounting Home-Based Business Human Resources & Employment Management & Leadership Marketing & Advertising Operations Sales Technology Women in Business > See All

Hiring & Firing Intellectual Property Internet & Technology Legal Mergers & Acquisitions Money & Fundraising Real Estate/Landlord-Tenant Sales & Marketing Starting a Business Business Guides Forms Kits > See All

Construction Medical Practices Restaurants Retail Trade Manufacturing Real Estate Wholesale Trade > See All

Accounting Advertising & Marketing Computers & Software Financial Services Human Resources Internet & Online Management Small Business > See All

Business Exchange Business Answers Buyer's Guides Franchise Opportunities Glossary White Papers Trials & Downloads Partner Resources Podcast Library Quote Center Video Library Web Site Tools > See All

Keep abreast of the latest news and trends in your industry. Browse through 5.6 million articles from over 1,300 periodicals.

HIV Treatment: ALERTS!

Issue Date: 04/01/2005

View Journal Archives

In This Issue

11-20 (of 54) related articles Sort by: Relevance \| Date Items per page
11. Antibiotic side effects. New precautions have been added to the labeling for the antibiotics Levaquin (levofloxacin) and Floxin (ofloxacin). The FDA has received reports of patients experiencing neuropathy ... (PERIODICAL ARTICLE) 12. Kaletra warning. Updates have been added to the labeling for the boosted protease inhibitor, Kaletra, that provide more information about the longer-term use of this med in ... (PERIODICAL ARTICLE) 13. Fewer pills for Invirase. A new 500-mg tablet of the HIV protease inhibitor, Invirase, is now available. Patients taking this new version now only need to take two 500-mg ... (PERIODICAL ARTICLE) 14. Hepatitis warnings with Epivir. New precautions have been added to the labeling for Epivir (3TC), Combivir (Epivir + Retrovir), Trizivir (Epivir + Ziagen + Retrovir), and Epzicom (Epivir + ... (PERIODICAL ARTICLE) 15. Sustiva warnings. New precautions have been added to the labeling for Sustiva regarding interactions with Vfend (voriconazole), a drug used to treat serious fungal infections. Sustiva reduces ... (PERIODICAL ARTICLE) 16. Caution: combination of Viread, Videx, and either Sustiva or Viramune. The combination of Viread, Videx, and either Sustiva or Viramune may cause early virologic failure in patients taking HIV needs for the first time. This ... (PERIODICAL ARTICLE) 17. Reyataz heart risks. New precautions have been added t0the labeling for Reyataz (an HIV protease inhibitor) for patients with existing heart problems. Specifically, some people have a problem ... (PERIODICAL ARTICLE) 18. FDA approves generic version of Videx EC delayed release capsules. In December 2004, the FDA approved a generic version of Didanosine (ddl) Delayed Release capsules (200 mg, 250 mg, and 400 mg) to use in ... (PERIODICAL ARTICLE) 19. Diarrhea dilemmas. Diarrhea is a common side effect of HIV medications and many patients take the drug loperamide (available over-the-counter as Imodium) to treat it. However, a ... (PERIODICAL ARTICLE) 20. Drugs for GI upset may interact with HIV protease inhibitors. According to a study presented at the 7th International Congress on Drug Therapy in HIV Infection in Glasgow, Scotland (abstract 206), many HIV+ people suffer ... (PERIODICAL ARTICLE)
11-20 (of 54) related articles Sort by: Relevance \| Date Items per page 11-20 (of 54) related articles Previous 123 4 5 6 Next

▼ - newer

older - ▼

2007

2005

2004

2003

2002

2001

Back to Professional Journals Home

Sponsored Links

Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.

© Copyright 2008 The Gale Group, Inc. All rights reserved.

You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.

Information and opinions on AllBusiness.com solely represent the thoughts and opinions of the authors and are not endorsed by, or reflect the beliefs of,
AllBusiness.com, its parent company D&B, and its affiliates.